top of page

Proteomics International (ASX PIQ), Research and Coverage

proteomics-international-laboratories-ltd

Proteomics International Laboratories Ltd (ASX: PIQ) is a medical diagnostics company based in Perth. It listed on the ASX on 16 April 2015 (ASX company data). It develops blood tests that measure proteins linked to disease, sold under the Promarker name. Promarker D, for the risk of kidney disease in people with diabetes, and Promarker Eso, to help rule out oesophageal cancer in people with chronic reflux, went on sale across Australia through Healius on 26 October 2026 (quarterly report, lodged 30 October 2026). The company expects to offer Promarker Endo, for endometriosis, between January and March 2027 (ASX announcements, 13 and 23 October 2026). Revenue was A$0.28 million in the year to 30 June 2026 (annual report, lodged 31 August 2026). Cash was A$1.8 million at 30 September 2026 (Appendix 4C, lodged 30 October 2026). Samso had published 10 pieces on the company at 17 November 2026.

ASX code: PIQ. Full legal name: Proteomics International Laboratories Ltd. Chief Executive Officer and Managing Director: David Morris. Dr James Williams is the non-executive chair. The other directors are Aaron Brinkworth, Paul House and Vicki Robinson, all non-executive (annual report, lodged 31 August 2026). Proteomics International held A$1.8 million in cash at 30 September 2026 and received a A$2.0 million research and development tax refund in October 2026. The quarterly cash flow report lists no loan facilities (quarterly report and Appendix 4C, lodged 30 October 2026).

Proteomics International tests and services

Proteomics International is a medical diagnostics company based in Perth. Proteomics is the study of proteins and what they do in the body. The company looks for biomarkers, which are proteins in the blood whose levels change with a disease. Each Promarker test measures a set of these proteins in a blood sample and combines the result with the patient's clinical data to give a risk result. The company has accredited laboratories in Australia and the United States (annual report, lodged 31 August 2026).

  • Promarker D. A blood test for people with type 2 diabetes. The company describes it as designed to predict the onset of diabetes-related chronic kidney disease up to four years before symptoms appear (annual report, lodged 31 August 2026). It is on sale in Australia at A$495 a test (ASX announcement, 23 October 2026).
  • Promarker Eso. A blood test for people with chronic reflux. It is designed to assist in ruling out oesophageal adenocarcinoma, a cancer of the oesophagus, the tube that carries food to the stomach (quarterly report, lodged 30 October 2026). It is on sale in Australia at A$997 a test (ASX announcement, 23 October 2026).
  • Promarker Endo. A blood test intended to give doctors additional information to support the assessment of patients with suspected endometriosis, a chronic condition in which tissue like the lining of the uterus grows outside it. It is not yet on sale. The company expects to make it available in Australia between January and March 2027, subject to preparing the test for clinical use and to quality, accreditation and regulatory requirements (ASX announcements, 13 and 23 October 2026).
  • OxiDx. A platform for measuring oxidative stress, held through a 66 per cent owned subsidiary. A strategic review of it is continuing (annual report, lodged 31 August 2026).
  • Analytical services. Protein analysis and contract research for industry and research customers. Revenue for the year to 30 June 2026 was A$278,015, made up of A$256,680 from analytical services and A$21,335 of licensing income (annual report, note 3, lodged 31 August 2026). Note 3 shows no separate line for sales of Promarker tests. The annual report says both tests were made available nationally in Australia during the year. The Healius rollout began after the year end.

The Healius rollout of Promarker D and Promarker Eso

Proteomics International sells its two available tests through Healius Limited (ASX: HLS), a pathology company. The agreement, signed in July 2026, makes Healius the exclusive Australian pathology distribution partner for the Promarker tests for three years, with a further three years by mutual agreement. Healius collects the blood samples at its collection centres and deals with referring doctors. Proteomics International does the testing and the clinical reporting. The commercial terms are confidential (ASX announcement, 22 July 2026).

Sales through Healius began in Western Australia and the Northern Territory on 14 September 2026 and nationally on 26 October 2026 (quarterly report, lodged 30 October 2026). The tests are sold on a private-pay basis, which means the patient pays for the test. The company says the revenue the agreement may generate cannot be reliably estimated at this early stage (ASX announcement, 23 October 2026). Before Healius, the company sold direct to consumers. It ended that model in Australia and the United States after a strategic review (annual report, lodged 31 August 2026).

The Australian laboratory holds NATA accreditation to ISO 15189, the standard for medical testing laboratories. The company describes the Promarker tests as laboratory-developed tests, meaning tests it develops and runs in its laboratory, and says the accreditation supports their clinical use. Public funding in Australia would need a review by the Medical Services Advisory Committee and a listing on the Medicare Benefits Schedule (annual report, lodged 31 August 2026).

In the United States, Promarker D has a billing code, and the federal Medicare agency has set a price of US$390.75 for it. The company states that this does not confer Medicare reimbursement, which needs a further technical assessment and a coverage decision. Reimbursement outcomes, it says, are not assured (annual report, lodged 31 August 2026). It targets a first United States distributor in the six months to June 2027 (quarterly report, lodged 30 October 2026).

Clinical evidence for the Promarker tests

Two measures describe how accurate a test is. Sensitivity is the share of people with the disease that a test correctly identifies. Specificity is the share of people without the disease that it correctly clears.

For Promarker D the company quotes sensitivity of 76 per cent and specificity of 92 per cent. For Promarker Eso it quotes 91 per cent and 98 per cent, and says the test is being validated across multiple cohorts, meaning groups of patients (investor presentation, 4 November 2026). The slides that carry these figures do not name a study or a patient number.

The annual report says results for Promarker D were published in The Journal of Applied Laboratory Medicine and the Internal Medicine Journal, and results for Promarker Eso in Diseases of the Esophagus (annual report, lodged 31 August 2026).

Proteomics International reported in October 2026 that it had validated Promarker Endo on an independent group of patients. The result was released in an ASX announcement, and the company cites no journal paper for it. The model was first built on samples from The Royal Women's Hospital in Melbourne and then refined. The fixed model was tested on a separate group from the University of Oxford. That group had 303 patients with surgically confirmed endometriosis and 125 patients with similar symptoms who were confirmed not to have it.

Sensitivity was 90 per cent for stage IV, the most severe stage, and 68 per cent across all four stages. Specificity was 71 per cent. On those figures, about 29 per cent of the patients confirmed not to have endometriosis had a positive result. The company says the initial performance figures it reported from The Royal Women's Hospital samples related to initial model development. The announcement does not state those figures. It also says stage I disease is harder to tell apart from patients with similar symptoms (ASX announcement, 13 October 2026). The investor presentation of 23 September 2026 quoted sensitivity of 83 per cent and specificity of 95 per cent for Promarker Endo.

Among its risks, the company notes that future studies may not confirm expected performance or may require more validation before broader adoption (annual report, lodged 31 August 2026).

Proteomics International revenue, cash and funding

Revenue was A$0.28 million in the year to 30 June 2026. Grants, interest and a A$2.17 million research and development tax incentive took total revenue and other income to A$3.61 million. The loss after tax was A$8.61 million (annual report, lodged 31 August 2026).

In the September 2026 quarter the company received A$264,000 from customers and used A$1.6 million in operations. The Appendix 4C divides the cash by that outflow and gives 1.1 quarters of funding. Counting the October tax refund, the company puts the figure at about 2.4 quarters (quarterly report and Appendix 4C, lodged 30 October 2026). A restructure in April 2026 made nine roles redundant, about a quarter of positions. Annual savings of more than A$1 million are expected (ASX announcement, 17 April 2026).

The annual accounts were prepared on a going concern basis. The directors say commercialising the Promarker tests will need future funding, and they describe a material uncertainty over the group continuing as a going concern. The same note says the group has a successful history of raising capital and of being eligible to claim the research and development tax incentive. Total liabilities were A$3.33 million against net assets of A$5.55 million at 30 June 2026. Of the liabilities, A$2.14 million was deferred income, mostly grant money received in advance (annual report, lodged 31 August 2026).

On 2 November 2026 the company announced a share purchase plan to raise up to A$5 million at 10 cents a share. It opened on 4 November 2026. The offer is not underwritten and is due to close on 25 November 2026. The company may accept oversubscriptions, close early or scale back applications. Each new share would carry one free option exercisable at 15 cents, if shareholders approve at the annual general meeting on 20 November 2026 (ASX announcement, 2 November 2026). The full A$5 million is expected to support operations to October 2027 (investor presentation, 4 November 2026).

Every Samso piece on Proteomics International

10 published pieces as at 17 November 2026, grouped by Samso product. Newest first in each group. Dates are Perth dates.

Samso News

Samso's most recent piece, of 30 January 2026, covered a Canadian patent for Promarker Eso. Since then the company has appointed Healius as its Australian distributor and reported the Oxford validation of Promarker Endo.

Questions people ask about Proteomics International (ASX PIQ)

What is the Proteomics International share price? The ASX website shows the PIQ share price. This page lists Samso's coverage and has no live price.

What is the latest announcement from Proteomics International? As at 17 November 2026 the newest item on the ASX list was a change of director's interest notice lodged on 11 November 2026.

Are the Promarker tests on sale? Promarker D and Promarker Eso have been available across Australia through Healius since 26 October 2026, at A$495 and A$997 a test. Promarker Endo was not on sale at 17 November 2026. The company expects it between January and March 2027.

Is Proteomics International worth looking at? This page gives no buy, sell or hold call, price target or valuation. Two Promarker tests are on sale across Australia through Healius, and the company says revenue from that agreement cannot yet be reliably estimated. The company reported in October 2026 that Promarker Endo had been validated on an independent Oxford group. It is not yet on sale. Cash was A$1.8 million at 30 September 2026, before a A$2.0 million tax refund. A share purchase plan was open at 17 November 2026, and the annual accounts describe a material uncertainty over going concern. Samso had published no research workup on Proteomics International at 17 November 2026. The Samso News piece of 30 January 2026 is the most recent.

Disclosure

Samso holds no shares in Proteomics International at 17 November 2026.

This page is general information only.

Depth over hype.

Samso company research pages are independent research commentary for general information only. Nothing on this page is financial product advice, and it does not take into account any reader's objectives, financial situation or needs. Figures are drawn from public sources believed reliable at the stated dates but are not guaranteed, and market-sensitive numbers change daily. Samso or associated parties may hold positions in, or have commercial arrangements with, companies mentioned. Seek professional advice before making investment decisions. © Samso 2026, samso.com.au

Page last reviewed 17 November 2026.

bottom of page